FDA clears Foundayo, the first oral GLP-1 for obesity, in fastest new drug approval since 2002
A once-daily GLP-1 tablet gives US patients a pill option for obesity, though price, insurance coverage and launch timing have not been disclosed.
The FDA approved Foundayo (orforglipron) on April 1, 2026, clearing the once-daily tablet for adults who have obesity, or who have overweight along with at least one weight-related health condition, to be taken with a reduced-calorie diet and more physical activity [2]. It is the first oral GLP-1 receptor agonist authorized for obesity in the United States [1], and the agency described it as the quickest new molecular entity approval since 2002 [2].
Two figures frame the speed. Regulators signed off 50 days after the submission was filed, and 294 days ahead of the application's PDUFA date of January 20, 2027 [2]. The filing moved through the Commissioner's National Priority Voucher pilot, launched in 2025; Foundayo is its first new molecular entity and its fifth approval overall, out of 18 vouchers awarded and six decisions issued so far [2]. The program aims for decisions within two months, with room for the agency's reviewers to extend that when they judge it necessary [2].
"This approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners," Commissioner Martin Makary said in the announcement [2]. Acting Center for Drug Evaluation and Research director Tracy Beth Høeg described the product as "a GLP-1 receptor partial agonist pill which does not need to be taken on an empty stomach" [2].
The FDA said two randomized, double-blind, placebo-controlled trials in adults with obesity, or with overweight and one or more related conditions, supported the decision. Across 72 weeks of treatment combined with diet and exercise, the agency reported weight loss that was statistically significant and clinically meaningful compared with placebo [2]. The average amount of weight lost was not given in the announcement. Coverage of the approval described a Phase 3 program that included a 3,127-person trial in people with obesity or overweight and comorbidities, and a 1,613-person trial in people with obesity or overweight and type 2 diabetes [1]. One trial had an extension phase in which participants with prediabetes continued for another two years [1].
The label lists nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, abdominal swelling, fatigue, burping, acid reflux, gas and hair loss among the side effects [2]. Warnings cover inflammation of the pancreas, severe gastrointestinal reactions, acute kidney injury from fluid loss, low blood sugar, allergic reactions, diabetic retinopathy in people with type 2 diabetes, gallbladder disease, and aspiration during general anesthesia or deep sedation [2]. A boxed warning flags thyroid C-cell tumors; the drug is not for people with a personal or family history of medullary thyroid cancer or with Multiple Endocrine Neoplasia syndrome type 2, and it should not be combined with another GLP-1 receptor agonist [2]. The label lays out a stepwise schedule, starting at 0.8 mg once daily and rising at intervals of at least 30 days, up to a maximum of 17.2 mg, based on response and tolerability [2].
Lilly reported first-quarter 2026 revenue of $19.8 billion, up 56% from the same period a year earlier, with reported earnings per share of $8.26, a 170% increase [1]. Non-GAAP earnings per share rose 156%, to $8.55, and the company raised full-year revenue guidance to $82.0 billion to $85.0 billion and non-GAAP earnings per share guidance to $35.50 to $37.00 [1].
Why it matters for patients
The obesity medicines most Americans have been prescribed so far are weekly injections: Wegovy (semaglutide) and Zepbound (tirzepatide) [1]. Foundayo adds a daily tablet, which coverage notes may appeal to people who avoid needles, get injection-site reactions, or simply prefer pills [1]. Orforglipron is a small molecule rather than a peptide, and that chemistry may ease manufacturing at a time when Lilly and Novo Nordisk have both struggled to keep pace with demand for injectables [1]. How the pill compares with injectable semaglutide or tirzepatide on weight loss has not been reported, and the FDA announcement did not disclose pricing, insurance coverage or a launch date [1][2]. Because the medicine is new, how people fare after stopping it has not been reported.
What happens next
The FDA will hold a public meeting on June 4, moved from June 12, to collect feedback on the voucher pilot, including eligibility rules, how vouchers are chosen, sponsor duties, pre-submission requirements, review procedures and the role of the program's review council [2]. Written comments are open through June 29, 2026 [2].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.